Evaluation of Speckle Tracking Parameters as Predictors of Successful VA SPECKLE ECMO
NCT ID: NCT03532529
Last Updated: 2018-12-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
24 participants
OBSERVATIONAL
2018-11-28
2019-11-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In order to achieve this purpose, speckle tracking analysis will be performed on the recorded images of the transoesophageal echocardiogram performed during the last VA ECMO weaning study of patients defined ready for VA ECMO liberation. VA ECMO liberation will be based according to LVOT VTI increase and clinical judgment during patients' VA ECMO weaning study. It will be assessed whether the population experiencing the outcomes of interest (death within 30 days from VA ECMO liberation, hospital admission for a new episode of cardiogenic shock or heart failure within 30 days from VA ECMO liberation, need for new mechanical circulatory support within 30 days from VA ECMO liberation) and the population not experiencing these outcomes have different values of strain (LV longitudinal and circumferential and RV longitudinal strain) during the weaning study.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The population consists of patients receiving VA ECMO mechanical circulatory support for cardiogenic shock, who have undergone an echocardiogram as part of the weaning process and a decision has been made to attempt weaning from VA ECMO. The decision to wean the patient from VA ECMO will be made by the attending clinician who will be aware of all echocardiographic measurements with the exception of the speckle tracking results (as is the standard-of-care at our institution). The study investigator who will perform all speckle tracking analysis will not be involved in the decision to wean from VA ECMO.
SCHEMATIC OF STUDY DESIGN
1. Screening of VA ECMO patients in whom a weaning study is planned
2. Definitive SCREENING FAILURE = patients who do not fulfil inclusion criteria or have at least one exclusion criterion (not including the LVOT VTI criterion)
3. VA ECMO weaning study performed
* Patients deemed unsuitable for liberation from VA ECMO at this time are not enrolled for analysis, and are reassessed following the next weaning study
* Patients deemed suitable for liberation from VA ECMO, but whose LVOT VTI was \<10cm at any stage of the weaning study, or whose LVOT VTI at lowest achieved flow was lower than baseline are excluded
* Patients deemed suitable for liberation from VA ECMO and not excluded based on LVOT VTI criterion are enrolled.
4. EVALUATION OF SPECKLE TRACKING FINDINGS (LV LONGITUDINAL AND CIRCUMFERENTIAL AND RV LONGITUDINAL STRAIN) AND CONVENTIONAL ECHOCARDIOGRAPHIC PARAMETERS WITH CLINICAL OUTCOMES AT 30 DAYS POST VA ECMO LIBERATION (REMOVAL)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
experiencing the composit outcome
Average values of LV longitudinal strain\^ (Midesophageal 4 chamber view) in patients who developed the composite outcome including the following outcomes of interest:
* death within 30 days from VA ECMO liberation
* the necessity of new Mechanical Circulatory Support (VA-ECMO, Impella, LVAD) within 30 days from VA ECMO liberation
o Whether after VA ECMO liberation the patient still needs IABP or a RVAD support, this situation is not considered necessity of new Mechanical Circulatory Support. A necessity of new Mechanical Circulatory Support is defined when IABP or RVAD or VA ECMO or Impella are needed again after their removal
* heart transplantation within 30 days from VA ECMO liberation
not applicable, it is an observational study
not applicable, it is an observational study
not experiencing the composit outcome
Average values of LV longitudinal strain\^ (Midesophageal 4 chamber view) in patients who did not develop the composite outcome including the following outcomes of interest:
* death within 30 days from VA ECMO liberation
* the necessity of new Mechanical Circulatory Support (VA-ECMO, Impella, LVAD) within 30 days from VA ECMO liberation
o Whether after VA ECMO liberation the patient still needs IABP or a RVAD support, this situation is not considered necessity of new Mechanical Circulatory Support. A necessity of new Mechanical Circulatory Support is defined when IABP or RVAD or VA ECMO or Impella are needed again after their removal
* heart transplantation within 30 days from VA ECMO liberation
not applicable, it is an observational study
not applicable, it is an observational study
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
not applicable, it is an observational study
not applicable, it is an observational study
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Receiving VA ECMO mechanical circulatory support for cardiogenic shock and planning to undergo an echocardiogram as part of a VA ECMO weaning study.
* Informed consent for study participation provided by the patient (where able) or personal consultee (where the patient is unable to provide consent) or nominated consultee (where the patient is unable to provide consent and no personal consultee is available).
Exclusion Criteria
* Patients who are expected to require heart transplantation, LVAD or biventricular VAD within 30 days from admission.
* Patients who are not expected to survive weaning from VA ECMO (liberation from VA ECMO exclusively for purpose of palliation).
* Contemporary presence of Impella device during VA ECMO weaning study.
* Patients in atrial fibrillation or in a different rhythm from sinus at the moment of VA ECMO weaning study.
* Patient's LVOT VTI is less than 10cm at any stage of VA ECMO weaning study and/or LVOT VTI is lower at the lowest achieved blood flow than it was at baseline (LVOT VTI criterion).
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Royal Brompton & Harefield NHS Foundation Trust
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Royal Brompton Hospital and Harefield NHS Foundation Trust
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Susanna Price, Chief Investigator
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
241001
Identifier Type: -
Identifier Source: org_study_id